Click here to create your personal news page. The news that appears on Schering will appear there and be constantly updated. You can then modify the page, share it with your friends, or export it and have it appear elsewhere.

You can also create a personal news page and follow the news that interests you by clicking on the tab labelled 'New page'.
 

topics : related - allExplore

Wikio Shopping

  1. 1. Computers
  2. 2. Electronics
  3. 3. Communication
  4. 4. Household Appliances
  5. 5. Car/Motor Bike
  6. 6. Digital Camera
  7. 7. Mobile Phone
  8. 8. Smartphone
  9. 9. PDA
  10. 10. GPS
  11. 11. LCD Monitor
  12. 12. Printer

New products

  1. 1. Sony KLV-40ZX1M
  2. 2. Lexmark X7675
  3. 3. Lexmark X4975ve
  4. 4. MSI Wind U100-1618XP
  5. 5. JVC DLA-HD750
  6. 6. Epson PowerLite Home Cinema 6100
  7. 7. Toshiba Gigaframe L80
  8. go to Shopping

Participate



Schering


Sort by : relevance - date - popularity
+Vote!

Epix regains commercialization rights to Vasovist

Bayer Schering Pharma is handing back the worldwide commercialization rights to Epix's Vasovist , an MRA agent that has yet to win FDA approval. Their deal ends on March 1, 2009 and Bayer Schering will continue to supply Vasovist to the 19 countries where it is marketed. The FDA had rejected Vasovist, saying that it needed additional testing. Epix resubmitted its NDA earlier this year. "We are pleased...

+Vote!

Schering Plough, Merck: Potential Cancer Concerns

Mark Barath submits: In a post on August 8 th , I advocated purchasing Schering Plough (SGP) and I spelled out my reasoning. In that post, I explained investor concerns of Vytorin. At that time, the ENHANCE panel found that Vytorin, a combination of Merck’s (MRK) Zocor and Schering’s Zetia, worked no better than Zocor alone at removing plaque from arteries. This information had the effect of reducing...

+Vote!

Bayer Schering Pharma To Support USAID With Contraceptives For Family Planning Programs

Bayer Schering Pharma AG, Germany, will supply up to 110 million cycles of oral contraceptives yearly for family planning programs supported by the U.S. Agency for International Development (USAID) in developing countries worldwide. This will allow more than 8 million women per year to have access to modern and reliable hormonal contraception. The contract was [...]

+Vote!

Winners & Losers: Fannie Mae Falls; Apple Shares Pop; Genentech Rejects Roche's Advances

TheStreet.com Winners & Losers Financial Winners & Losers: Fannie Mae Tech Winners & Losers: Apple 8/13/2008 2:47 PM EDT Health Winners & Losers: Genentech 8/13/2008 4:59 PM EDT Schering Regroups After FDA Rejection 8/13/2008 4:49 PM EDT OPINION: U.S. Contracts in Iraq at What Cost? A new study by the Congressional Budget Office puts the spotlight on the billions of U.S. taxpayer dollars going to private...

+Vote!

Schering Regroups After FDA Rejection

The company plans to rely on the sales of other drugs, particularly in overseas markets.

+Vote!

Schering Drug Derailed by Power of One

A single patient's allergic reaction may have delayed U.S. approval by up to three years.

+Vote!

Reportlinker.com: Bayer Schering Pharma AG: Company Profile

LONDON, UNITED KINGDOM (MARKET WIRE) Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.

+Vote!

Alemtuzumab: Infection-Related Deaths

By Anonymous United Kingdom - Bayer Schering Pharma AG and Genzyme Europe BV have informed physicians of six infectionrelated deaths, reported from a trial (CALGB10101) in which previously untreated, symptomatic B-cell chronic lymphocytic leukemia (CLL) patients were treated with fludarabine and rituximab followed by alemtuzumab for remission consolidation.

+Vote!

Male birth control!

The Long Wait for Male Birth Control By Adam Goodman Just a few years ago, the new male contraceptive seemed like an inevitable reality. Major pharmaceutical companies like Wyeth, Schering and Organon were pumping millions into hormonal birth-control development programs for men, and researchers were breathlessly promising imminent production. more here

+Vote!

ANALYSIS-US FDA caution seen with Schering drug denial

Source: Reuters (Adds FDA comment) By Lisa Richwine WASHINGTON, Aug 1 (Reuters) - The unusual rejection of an experimental drug that had unanimous support from outside experts signals further caution by the U.S. ...

+Vote!

Safety Scares Hit Elan, Biogen And Schering

A barrage of worries about drug risks batter the stocks of several drug makers.

+Vote!

ANALYSIS-US FDA caution seen with Schering drug rejection

Source: Reuters By Lisa Richwine WASHINGTON, Aug 1 (Reuters) - The unusual rejection of an experimental drug with unanimous support from outside experts signals further caution by the U.S. Food and Drug ...

+Vote!

FDA rejects Schering drug to reverse anesthesia

Government regulators dealt a major setback to Schering-Plough Corp., rejecting a highly anticipated drug designed to help patients recover from anesthesia.

+Vote!

FDA rejects Schering drug to reverse anesthesia

Government regulators dealt a major setback to Schering-Plough Corp., rejecting a highly anticipated drug designed to help patients recover from anesthesia.

+Vote!

FDA rejects Schering drug to reverse anesthesia

Government regulators dealt a major setback to Schering-Plough Corp., rejecting a highly anticipated drug designed to help patients recover from anesthesia. The Food and Drug Administration notified the company Thursday that it will not approve its drug...